Journal: bioRxiv

Article Title: ProAgio, a Novel Integrin αvβ3 Targeted Cytotoxin, Suppresses Tumor Growth and Reprograms the PDAC Microenvironment

doi: 10.64898/2026.01.15.699725

Figure Lengend Snippet: (A) Representative IHC staining of ITGB3 in PDAC tissue microarrays (TMA) showing varying expression levels in non-cancer and cancer tissue sections. (B). High magnification IHC images demonstrating the expression of ITGB3 on normal pancreas and cancer cells with stromal regions. (D-I) . Scatter plots depicting the correlation between ITGB3 and key tumor-associated markers such as HIF-1α (D) , GLUT-1 (E) , VEGFA (F) , Vimentin (G) , COL1A1 (H) , and PECAM1 (I) . Pearson correlation coefficients (R) and p -values indicate statistically significant positive correlation between ITGB3 and these markers. Statistical significance was assessed using a two-tailed unpaired Student’s t-test. All quantitative data represent the mean ± SEM. ∗∗∗∗p < 0.0001.

Article Snippet: To evaluate the role of ITGB3 in PDAC, we analyzed its expression using IHC in a human PDAC tissue array (PA483-L97, Biomax) that contains 40 cancer and eight non-cancer tissues ( Supplementary Table 1 ).

Techniques: Immunohistochemistry, Expressing, Two Tailed Test

Journal: Nature

Article Title: Loss of colonic fidelity enables multilineage plasticity and metastasis

doi: 10.1038/s41586-025-09125-5

Figure Lengend Snippet: (a) International Cancer Genome Consortium data of top 20 mutated cancer genes with high functional impact mutations in colorectal cancer (CRC). (b) Representative ATRX staining of human normal and CRC tissue microarray. Examples of positive and negative staining are shown. Scale bars, 500 µm. (c) Quantification of ATRX expression using immunohistochemistry H-score method analysed using QuPath. Samples are separated into normal, non-metastatic (stage I and II) and metastatic (stage III and IV) groups, n = 8 vs 47 vs 25 tumours. (d) Summary data indicating presence (H-score > 10) or absence (H-score <10) of ATRX staining in non-metastatic and metastatic samples. Number of tumours in each group indicated on graph, n = 47 vs 25 tumours. (e) Summary data indicating presence or absence of ATRX mutation in CRIS-B vs all other CRIS transcriptional subtypes. Data extracted from TCGA dataset where CRIS tumour annotation is known. Number of tumours in each group indicated on graph, n = 43 vs 278 tumours. (f) Overall survival data of patients with CRIS-B tumours separated on presence or absence of ATRX mutation. Data extracted from TCGA dataset, n = 37 vs 6 patients. For (c) data are mean ± SD. P values were calculated using ordinary one-way ANOVA with multiple comparisons. For (d) and (e) p values were calculated using two-sided Fisher’s exact test. For (f) P value was calculated using Log-rank (Mantel-Cox) test. (g) Lollipop plot of TCGA PanCancer mutational data for ATRX. ATRX mutations were analysed using cBioPortal (07/12/23) with TCGA PanCancer Atlas Studies selected. (h) Western-blot analysis of AKP ATRX KO organoids for ATRX and β-actin. n = 2 technical replicates. (i) Representative images of haematoxylin and eosin (H&E) stained lung metastases in mice injected with AKP Control or AKP Atrx KO2 organoid cells via tail vein. Scale bars, 500 µm. (j) Quantification of number of lung metastases per mouse, n = 7 vs 8 mice. (k) Quantification of total lung tumour burden per mouse, n = 7 vs 8 mice. (l) Summary data indicating presence or absence of lung metastases. Number of mice with lung metastases or no metastases indicated on graph, n = 7 vs 8 mice. For (j) and (k) data are mean ± SD. P values were calculated using two-tailed Mann-Whitney test. For (l) p value was calculated using two-sided Fisher’s exact test.

Article Snippet: The commercial colon cancer human tissue array used was CO804b (Biomax) (Extended Data Fig. ).

Techniques: Functional Assay, Staining, Microarray, Negative Staining, Expressing, Immunohistochemistry, Mutagenesis, Western Blot, Injection, Control, Two Tailed Test, MANN-WHITNEY